Wallace Max N. 4

4 · Humacyte, Inc. · Filed Aug 27, 2021

Form 4

Period: 2021-08-26

Director

Transactions

Award
Stock Options (right to buy)
2021-08-26+6,564→ 6,564 total
Exercise: $1.19Exp: 2023-11-22→ Common Stock (6,564 underlying)
Award
Common Stock
2021-08-26+49,986→ 49,986 total
Award
Stock Options (right to buy)
2021-08-26+13,129→ 13,129 total
Exercise: $2.56Exp: 2025-09-01→ Common Stock (13,129 underlying)
Award
Stock Options (right to buy)
2021-08-26+17,068→ 17,068 total
Exercise: $6.54Exp: 2028-04-12→ Common Stock (17,068 underlying)

Footnotes (3)

[F1]On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
[F2]Options are fully vested and exercisable.
[F3]As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.

Documents

1 file